BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Xenon Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Xenon Pharmaceuticals's drugs run
 \, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06922110-819@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Azetukalner: Phase 3 readout est. (NCT06922110)
DESCRIPTION:Azetukalner\, phase 3\, Major Depressive Disorder.\nStudy: An O
 pen-Label Study of Azetukalner in Major Depressive Disorder\nEstimated pri
 mary completion: January 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/azetukalner#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06922110
URL:https://assetmemo.bio/drug/azetukalner#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05667142-819@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Azetukalner: Phase 3 readout est. (NCT05667142)
DESCRIPTION:Azetukalner\, phase 3\, Epilepsy.\nStudy: A Study to Evaluate X
 EN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures\
 nEstimated primary completion: April 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/azetukalner#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05667142
URL:https://assetmemo.bio/drug/azetukalner#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07076407-819@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Azetukalner: Phase 3 readout est. (NCT07076407)
DESCRIPTION:Azetukalner\, phase 3\, Major Depressive Disorder.\nStudy: A Ra
 ndomized Study of Azetukalner Versus Placebo in Major Depressive Disorder 
 (X-NOVA3)\nEstimated primary completion: May 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/azetukalner#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07076407
URL:https://assetmemo.bio/drug/azetukalner#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05716100-819@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Azetukalner: Phase 3 readout est. (NCT05716100)
DESCRIPTION:Azetukalner\, phase 3\, Epilepsy.\nStudy: A Randomized Study of
  XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)\nEstimated prima
 ry completion: January 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/azetukalner#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05716100
URL:https://assetmemo.bio/drug/azetukalner#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07172516-819@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Azetukalner: Phase 3 readout est. (NCT07172516)
DESCRIPTION:Azetukalner\, phase 3.\nStudy: A Randomized Study of Azetukalne
 r Versus Placebo in Depressive Episodes Associated With Bipolar I or II Di
 sorder (Bipolar Depression)\nEstimated primary completion: June 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/azetukalner#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07172516
URL:https://assetmemo.bio/drug/azetukalner#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07217860-819@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Azetukalner: Phase 3 readout est. (NCT07217860)
DESCRIPTION:Azetukalner\, phase 3.\nStudy: An Open-label Study of Azetukaln
 er in Bipolar I or II Depression (X-CEED-OLE)\nEstimated primary completio
 n: June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azetuka
 lner#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07217860
URL:https://assetmemo.bio/drug/azetukalner#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05718817-819@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20330430
DTEND;VALUE=DATE:20330501
SUMMARY:Azetukalner: Phase 3 readout est. (NCT05718817)
DESCRIPTION:Azetukalner\, phase 3\, Epilepsy.\nStudy: An Open-label Study o
 f XEN1101 in Epilepsy\nEstimated primary completion: April 2033. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/azetukalner#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05718817
URL:https://assetmemo.bio/drug/azetukalner#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
